243 related articles for article (PubMed ID: 15928483)
1. The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy.
Querfeld C; Rosen ST; Guitart J; Kuzel TM
Curr Opin Hematol; 2005 Jul; 12(4):273-8. PubMed ID: 15928483
[TBL] [Abstract][Full Text] [Related]
2. Mycosis fungoides and the Sézary syndrome.
Foss F
Curr Opin Oncol; 2004 Sep; 16(5):421-8. PubMed ID: 15314509
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous lymphomas: a review with current treatment options.
Querfeld C; Guitart J; Kuzel TM; Rosen ST
Blood Rev; 2003 Sep; 17(3):131-42. PubMed ID: 12818223
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
6. Bridging the specialty gap: Update on primary cutaneous lymphomas.
Olsen EA; Hodak E; Geskin L; Scarisbrick J;
J Am Acad Dermatol; 2024 Feb; 90(2):257-260. PubMed ID: 38043039
[No Abstract] [Full Text] [Related]
7. Memorials and mandates for cutaneous lymphomas.
Heald PW
Arch Dermatol; 2003 Jul; 139(7):926-8. PubMed ID: 12873891
[No Abstract] [Full Text] [Related]
8. Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.
Devata S; Wilcox RA
Am J Clin Dermatol; 2016 Jun; 17(3):225-37. PubMed ID: 26923912
[TBL] [Abstract][Full Text] [Related]
9. T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: history and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL).
Bunn PA; Foss FM
J Cell Biochem Suppl; 1996; 24():12-23. PubMed ID: 8806090
[TBL] [Abstract][Full Text] [Related]
10. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).
Kim YH; Willemze R; Pimpinelli N; Whittaker S; Olsen EA; Ranki A; Dummer R; Hoppe RT;
Blood; 2007 Jul; 110(2):479-84. PubMed ID: 17339420
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
Whittaker SJ; Foss FM
Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
[TBL] [Abstract][Full Text] [Related]
12. Management of the cutaneous peripheral T-cell lymphomas: when subtypes matter.
Choi MY; Lechowicz MJ
Cancer J; 2012; 18(5):439-44. PubMed ID: 23006949
[TBL] [Abstract][Full Text] [Related]
13. Therapy of cutaneous lymphoma--current practice and future developments.
Dummer R; Kempf W; Hess Schmid M; Häffner A; Burg G
Onkologie; 2003 Aug; 26(4):366-72. PubMed ID: 12972705
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous T-cell lymphomas: a review with emphasis on new treatment approaches.
Querfeld C; Rosen ST; Kuzel TM; Guitart J
Semin Cutan Med Surg; 2003 Sep; 22(3):150-61. PubMed ID: 14649582
[TBL] [Abstract][Full Text] [Related]
15. Are we there yet? cellular therapies for cutaneous T cell lymphoma.
Atilla PA; Atilla E
Curr Res Transl Med; 2023; 71(2):103390. PubMed ID: 37062252
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy.
Querfeld C; Kuzel TM; Guitart J; Rosen ST
Oncology (Williston Park); 2007 May; 21(6):689-96; discussion 699-700,. PubMed ID: 17564326
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostics of primary cutaneous lymphomas].
Felcht M; Hillen U; Klemke CD
Hautarzt; 2017 Sep; 68(9):696-701. PubMed ID: 28779267
[TBL] [Abstract][Full Text] [Related]
18. Management of the primary cutaneous lymphomas.
Prince HM; McCormack C; Ryan G; O'Keefe R; Seymour JF; Baker C
Australas J Dermatol; 2003 Nov; 44(4):227-40; quiz 241-2. PubMed ID: 14616487
[TBL] [Abstract][Full Text] [Related]
19. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
Ramelyte E; Dummer R; Guenova E
Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
[No Abstract] [Full Text] [Related]
20. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.
Marolleau JP; Baccard M; Flageul B; Rybojad M; Laroche L; Vérola O; Brandely M; Morel P; Gisselbrecht C
Arch Dermatol; 1995 May; 131(5):574-9. PubMed ID: 7741545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
